Sutro has published the first phase clinical results of its ADC products against ovarian cancer
-
Last Update: 2019-10-30
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Sutro biopharma, located in San Francisco, California, USA, is a research, development and production enterprise of tumor drugs whose products are in clinical stage The company today released data on the safety and potential anticancer activity of stro-002, an anti folate alpha receptor antibody drug conjugate, in a preclinical xenotransplantation (PDX) model derived from patients with endometrial cancer The ongoing phase I trial is an open label, multicenter, incremental dose study to determine the MTD of stro-002, evaluate the safety, tolerability, and preliminary antitumor activity of stro-002, and find the recommended phase II dose So far, the company has applied stro-002 to 13 patients in phase I study, but has not found the maximum tolerable dose (MTD) Two of the patients received 6 mg / kg of the drug and showed normal performance during the DLT observation period The company will increase its usage in the future So far, there is no DLT and infusion response in these patients who have received a lot of treatment Preliminary evidence of antitumor activity was observed in patients with partial response confirmed by the RECIST 1.1 standard (Biovalley / BIOON Com) original source: SURTO official website
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
